

WHAT IS CLAIMED IS:

1. A compound having the structure



.

2. A pharmaceutically acceptable salt of a compound having the structure



.

3. The pharmaceutically acceptable salt according to claim 2, which is a monohydrochloride salt.

4. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

5. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 2 and a pharmaceutically acceptable carrier or diluent.

6. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 3 and a pharmaceutically acceptable carrier or diluent.

7. The compound according to claim 1 for use in therapy.

8. The pharmaceutically acceptable salt according to claim 2 for use in therapy.

9. The pharmaceutically acceptable salt according to claim 3 for use in therapy.

10. The pharmaceutical composition according to claim 4 for use in therapy.

11. The pharmaceutical composition according to claim 5 for use in therapy.

12. The pharmaceutical composition according to claim 6 for use in therapy.

13. Use of the compound according to claim 1 in the manufacture of a medicament for treating systemic lupus erythematosus in a patient.

14. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating systemic lupus erythematosus in a patient.

15. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating systemic lupus erythematosus in a patient.

16. Use of the compound according to claim 1 in the manufacture of a medicament for treating psoriasis in a patient.

17. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating psoriasis in a patient.

18. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating psoriasis in a patient.

19. Use of the compound according to claim 1 in the manufacture of a medicament for treating psoriatic arthritis in a patient.

20. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating psoriatic arthritis in a patient.

21. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating psoriatic arthritis in a patient.

22. Use of the compound according to claim 1 in the manufacture of a medicament for treating lupus nephritis in a patient.

23. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating lupus nephritis in a patient.

24. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating lupus nephritis in a patient.

25. Use of the compound according to claim 1 in the manufacture of a medicament for treating Sjögren's syndrome in a patient.

26. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating Sjögren's syndrome in a patient.

27. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating Sjögren's syndrome in a patient.

28. Use of the compound according to claim 1 in the manufacture of a medicament for treating inflammatory bowel disease in a patient.

29. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating inflammatory bowel disease in a patient.

30. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating inflammatory bowel disease in a patient.

31. Use of the compound according to claim 1 in the manufacture of a medicament for treating Crohn's disease in a patient.

32. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating Crohn's disease in a patient.

33. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating Crohn's disease in a patient.

34. Use of the compound according to claim 1 in the manufacture of a medicament for treating ankylosing spondylitis in a patient.

35. Use of the pharmaceutically acceptable salt according to claim 2 in the manufacture of a medicament for treating ankylosing spondylitis in a patient.

36. Use of the pharmaceutically acceptable salt according to claim 3 in the manufacture of a medicament for treating ankylosing spondylitis in a patient.

37. Use of a composition in the manufacture of a medicament for treating psoriasis in a subject, wherein the composition comprises the compound according to claim 1, wherein the composition is to be orally administered to the subject.

38. The use according to claim 37, wherein the composition is in the form of a tablet, a capsule, granules, a powder, or a liquid formulation.

39. The use according to claim 38, wherein the composition is in the form of a tablet.

40. The use according to claim 38, wherein the composition is in the form of a capsule.

41. The use according to claim 38, wherein the composition is in the form of granules.

42. The use according to claim 38, wherein the composition is in the form of a powder.

43. The use according to claim 38, wherein the composition is in the form of a liquid formulation.

44. The use according to claim 43, wherein the composition is in the form of a syrup.

45. The use according to claim 37, wherein the composition is to be orally administered to the subject 1 to 4 times per day.

46. The use according to claim 45, wherein the composition is in the form of a tablet.

47. Use of a tablet in the manufacture of a medicament for treating psoriasis in a subject, wherein the tablet comprises the compound according to claim 1, wherein the tablet is to be administered orally to the subject, 1 to 2 times per day.

48. The use according to claim 47, wherein one tablet per day is to be administered to the subject.


49. The use according to claim 47, wherein two tablets per day are to be administered to the subject.

50. Use of a tablet in the manufacture of a medicament for treating psoriasis in a subject, wherein the tablet comprises the pharmaceutically acceptable salt according to claim 2, wherein the tablet is to be orally administered to the subject, 1 to 2 times per day.

51. The use according to claim 50, wherein one tablet per day is to be administered to the subject.

52. The use according to claim 50, wherein two tablets per day are to be administered to the subject.

~~for use in the treatment of an inflammatory or autoimmune disease wherein the compound has the following formula I:~~



~~I~~

~~or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:~~

~~Y is N or CR_6;~~

~~R^1 is selected from H and C_{1-3}alkyl or C_{3-6}cycloalkyl, each optionally substituted by 0-7 R^{1a};~~

~~R^{1a} at each occurrence is independently hydrogen, deuterium, F, Cl, Br or CN;~~

~~R^2 is $-C(O)R^{2a}$; or C_{1-6}alkyl, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a} or a 5-14 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, each group substituted with 0-4 R^{2a};~~

~~R^{2a} at each occurrence is independently hydrogen, =O, halo, OCF_3, CN, NO_2, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rC(O)OR^b$, $-(CH_2)_rOC(O)R^b$, $CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-(CH_2)_rNR^bC(O)OR^e$, $-NR^bC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)_pR^e$, C_{1-6} alkyl substituted with 0-3 R^a, C_{1-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^a, C_{2-6} alkynyl substituted with 0-3 R^a, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-1

R^a or a $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms or 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-2 R^a;

R^3 is C_{3-10} cycloalkyl, C_{6-10} aryl or a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, each group substituted with 0-4 R^{3a};

R^{3a} at each occurrence is independently hydrogen, =O, halo, OCF_3, CF_3, CHF_2, CN, NO_2, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rC(O)OR^b$, $-(CH_2)_rOC(O)R^b$, $-(CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-(CH_2)_rNR^bC(O)OR^e$, $-NR^bC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)_pR^e$, C_{1-6} alkyl substituted with 0-3 R^a, C_{2-6} alkenyl substituted with 0-3 R^a, C_{2-6} alkynyl substituted with 0-3 R^a,

C_{1-6} haloalkyl, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-3 R^a or a $-(CH_2)_r$-5-10 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^a;

or two R^{3a}, together with the atoms to which they are attached, combine to form a fused ring wherein said ring is selected from phenyl and a heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, each fused ring substituted with 0-3 R^{a1};

R^4 and R^5 are independently hydrogen, C_{1-4} alkyl substituted with 0-1 R^f, $(CH_2)_r$ phenyl substituted with 0-3 R^d or a $-(CH_2)$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$;

R^6 is hydrogen, halo, C_{1-4}alkyl, C_{1-4}haloalkyl, OC_{1-4}haloalkyl, OC_{1-4}alkyl, CN, NO_2 or OH;

R^{11} at each occurrence is independently hydrogen, C_{1-4} alkyl substituted with 0-3 R^f, CF_3, C_{3-10} cycloalkyl substituted with 0-1 R^f, $(CH)_r$ phenyl substituted with 0-3 R^d or $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^d;

R^a and R^{a1} at each occurrence are independently hydrogen, F, Cl, Br, OCF_3, CF_3, CHF_2, CN, NO_2, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rC(O)OR^b$, $-(CH_2)_rOC(O)R^b$, $-(CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-(CH_2)_rNR^bC(O)OR^e$, $-NR^bC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)R^e$, $-S(O)_2R^e$, C_{1-6} alkyl substituted with 0-3 R^f, C_{1-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^a, C_{2-6} alkynyl substituted with 0-3 R^a, $-(CH_2)_r$-3-14 membered

carbocycle or -$(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^f;

R^b is hydrogen, C_{1-6} alkyl substituted with 0-3 R^d, C_{1-6} haloalkyl, C_{3-6} cycloalkyl substituted with 0-2 R^d, or -$(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^f or $(CH_2)_r$-phenyl substituted with 0-3 R^d;

R^e is C_{1-6} alkyl substituted with 0-3 R^f, $(CH_2)_r$-C_{3-6} cycloalkyl substituted with 0-3 R^f or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^d at each occurrence is independently hydrogen, F, Cl, Br, OCF_3, CF_3, CN, NO_2, $-OR^e$, -$(CH_2)_r C(O)R^e$, $-NR^eR^e$, $-NR^eC(O)OR^e$, C_{1-6} alkyl or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^e at each occurrence is independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl and $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^f independently at each occurrence is hydrogen, halo, CN, NH_2, OH, C_{3-6} cycloalkyl, CF_3, $O(C_{1-6}$alkyl) or a -$(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$;


p is 0, 1, or 2; and

r is 0, 1, 2, 3, or 4.

2. A compound of claim 1, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^2 is -$C(O)R^{2a}$; or C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl or pyrrolopyridinyl, each group substituted by 0-4 groups selected from R^{2a}.

3. A compound according to any one of claims 1-2, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein both R^4 and R^5 are hydrogen.

4. A compound according to any one of claims 1-3 having the following formulae:



~~or~~

~~or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:~~

~~R^1 is H or C_{1-3}alkyl substituted by 0-7 R^{1a};~~

~~R^{1a} at each occurrence is independently hydrogen, deuterium or halogen;~~

~~R^2 is $-C(O)R^{2a}$; or C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl or pyrrolopyridinyl, each group substituted by 0-4 groups selected from R^{2a};~~

~~R^{2a} at each occurrence is independently hydrogen, =O, halo, CN, $-(CH_2)_rOR^b$, $-(CH_2)_rC(O)R^b$, $-NR^bC(O)R^e$, $-C(O)OR^b$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-C_{1-6}$alkyl substituted with 0-3 R^a, C_{1-6} haloalkyl, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^a or a $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-2 R^a;~~

~~R^3 is C_{3-10} cycloalkyl, a C_{6-10} aryl, or a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, each group substituted with 0-4 R^{3a};~~

~~R^{3a} at each occurrence is independently hydrogen, halo, OCF_3, CF_3, CHF_2, CN, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)_pR^e$, C_{1-6} alkyl substituted with 0-3 R^a, C_{1-6} haloalkyl, a $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-3 R^a or a $-(CH_2)_r$-5-10 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^a;~~

~~or two R^{3a}, together with the atoms to which they are attached, combine to form a fused ring wherein that ring is selected from phenyl and a 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O, each fused ring substituted, as valence allows, by 0-3 R^a;~~

~~R^{11} at each occurrence is independently hydrogen, C_{1-4} alkyl substituted with 0-3 R^f or C_{3-6}cycloalkyl substituted with 0-1 R^f;~~

~~R^a at each occurrence is hydrogen, =O, F, $-(CH_2)_rOR^b$ or C_{1-6}alkyl substituted with 0-3 R^f;~~

R^b is hydrogen, C_{1-6} alkyl substituted with 0-3 R^d, C_{1-6} haloalkyl, C_{3-6} cycloalkyl substituted with 0-2 R^d, or $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^f; or $(CH_2)_r$-phenyl substituted with 0-3 R^d;

R^e is C_{1-6} alkyl substituted or C_{3-6} cycloalkyl, each group substituted with 0-3 R^f;

R^d at each occurrence is independently hydrogen, F, Cl, Br or -OH;

R^f at each occurrence is independently hydrogen, halo, CN, OH or $O(C_{1-6}alkyl)$;


p is 0, 1 or 2; and









r is 0, 1 or 2.




5. A compound according to any one of claims 1-4, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^2 is pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl or quinolinyl, each group substituted with 0-3 R^{2a}.

6. A compound according to any one of claims 1-4, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^2 is $-C(O)R^{2a}$; or C_{1-6}alkyl, C_{3-6}cycloalkyl or phenyl substituted with 0-3 R^{2a}.

7. A compound according to any one of claims 1-5, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^2 is:



8. A compound according to any one of claims 1-7, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^3 is phenyl, cyclopentyl, cyclohexyl, triazolyl, oxadiazolyl, pyrimidinyl, tetrazolyl, pyrazolyl, thiazolyl, furanyl, or pyranyl, each group substituted with 0-4 R^{3a}. (Especially phenyl substituted with 0-4 R^{3a}).

9. A compound according to any one of claims 1-8, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:

R^{3a} at each occurrence independently is hydrogen, Ph, CN, NH_2, OCF_3, OR^b, halo, cycloalkyl, $C(O)NR^{11}R^{11}$, $S(O)_2NR_{11}R_{11}$, $C(O)R^b$, SO_pR^e, $NR^bSO_pR^e$, $NR^bC(O)R^e$, haloalkyl, CN, 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O substituted with 0-3 R^a and C_{1-6} alkyl substituted with 0-3 R^a; or

one R^{3a} and a second R^{3a}, together with the atoms to which they are attached, combine to form a fused 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O or phenyl;

R^{11} at each occurrence independently is hydrogen, C_{3-6} cycloalkyl substituted with 0-3 R^f, or C_{1-4}alkyl substituted with 0-1 R^f;

R^a independently at each occurrence is C_{1-6} alkyl substituted with 0-3 R^f, halo (F) or OR^b;

R^b independently at each occurrence is hydrogen, 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O substituted with 0-3 R^f, or C_{1-6} alkyl substituted with 0-3 R^d;


R^d independently at each occurrence is F, Cl, Br or OH;

R^e independently at each occurrence is C_{1-6} alkyl or C_{3-6} cycloalkyl, each group substituted with 0-3 R^f substituted with 0-3 R^f;

R^f independently at each occurrence is hydrogen, halo or OH; and

p is 2.

10. A compound according to any one of claims 1-9, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:

R^3 is 

;

R^{3aa} is $S(O)_pR^e$, OR^b, chloro, F, CN, NH_2, $C(O)NR^{11}R^{11}$, $NR^bSO_pR^e$, $NR^bC(O)R^e$, C_{1-6} alkyl substituted with 0-3 R^a or a 5- to 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S substituted with 0-3 R^{3a}; (especially, R^{3aa} is $S(O)_2Me$ or OMe)

R^{3ab}, R^{3ac}, or R^{3ad} are independently hydrogen, Cl, F, Br, CN, OR^b, C_{1-6} alkyl substituted 0-3 R^a; $C(O)NR^{11}R^{11}$, $C(O)R^b$, S(O)pRc, or a 4-7 membered heterocycle containing1-3 heteroatoms selected from N, O, and S substituted with 0-3 R^a; (especially R^{3ab}, R^{3ac}, or R^{3ad} are independently, hydrogen or 5-6 membered heterocycle containing1-3 heteroatoms selected from N, O, and S substituted with 0-2 R^a;

R^{11} at each occurrence independently is hydrogen, cyclopropyl substituted with 0-3 R^f or C_{1-4}alkyl substituted with 0-3 R^f;

R^a at each occurrence independently is C_{1-6} alkyl substituted with 0-3 R^f, OR^b or halo;

R^b at each occurrence independently is hydrogen, C_{1-6} alkyl substituted with 0-2 R^d or a 5- to 7-membered heterocycle containing 1-3 heteroatoms selected from N, O and S;

R^e at each occurrence independently is C_{1-6} alkyl substituted with 0-3 R^f;

~~R^d at each occurrence independently is F or OH;~~


~~R^f at each occurrence independently is halo or OH; and~~









~~p is 0-2.~~








~~11. A compound according to claim 10, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^{3aa} is $S(O)_pR^e$ or $C(O)NR^{11}R^{11}$.~~







~~12. A compound according claim 10, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^{3aa} is OR^b.~~


~~13. A compound according to any one of claims 1-11, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R^3 is:~~















14. Use of a compound in the manufacture of a medicament in the treatment of an inflammatory or autoimmune disease wherein the compound has the following formula I:



I

or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:

Y is N or CR_6;

R^1 is selected from H and C_{1-3}alkyl or C_{3-6}cycloalkyl, each optionally substituted by 0-7 R^{1a};

R^{1a} at each occurrence is independently hydrogen, deuterium, F, Cl, Br or CN;

R^2 is $-C(O)R^{2a}$; or C_{1-6}alkyl, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a} or a 5-14 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, each group substituted with 0-4 R^{2a};

R^{2a} at each occurrence is independently hydrogen, =O, halo, OCF_3, CN, NO_2, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rC(O)OR^b$, $-(CH_2)_rOC(O)R^b$, $CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-(CH_2)_rNR^bC(O)OR^e$, $-NR^bC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)_pR^e$, C_{1-6} alkyl substituted with 0-3 R^a, C_{1-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^a, C_{2-6} alkynyl substituted with 0-3 R^a, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^a or a $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms or 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-2 R^a;

R^3 is C_{3-10} cycloalkyl, C_{6-10} aryl or a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, each group substituted with 0-4 R^{3a};

R^{3a} at each occurrence is independently hydrogen, =O, halo, OCF_3, CF_3, CHF_2, CN, NO_2, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rC(O)OR^b$, $-(CH_2)_rOC(O)R^b$, $-(CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-(CH_2)_rNR^bC(O)OR^e$, $-NR^bC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)_pR^e$, C_{1-6} alkyl substituted with 0-3 R^a, C_{2-6} alkenyl substituted with 0-3 R^a, C_{2-6} alkynyl substituted with 0-3 R^a,
C_{1-6} haloalkyl, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-3 R^a or a $-(CH_2)_r$-5-10 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^a;

or two R^{3a}, together with the atoms to which they are attached, combine to form a fused ring wherein said ring is selected from phenyl and a heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, each fused ring substituted with 0-3 R^{a1};

R^4 and R^5 are independently hydrogen, C_{1-4} alkyl substituted with 0-1 R^f, $(CH_2)_r$ phenyl substituted with 0-3 R^d or a $-(CH_2)$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$;

R^6 is hydrogen, halo, C_{1-4}alkyl, C_{1-4}haloalkyl, OC_{1-4}haloalkyl, OC_{1-4}alkyl, CN, NO_2 or OH;

R^{11} at each occurrence is independently hydrogen, C_{1-4} alkyl substituted with 0-3 R^f, CF_3, C_{3-10} cycloalkyl substituted with 0-1 R^f, $(CH)_r$ phenyl substituted with 0-3 R^d or $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^d;

R^a and R^{a1} at each occurrence are independently hydrogen, F, Cl, Br, OCF_3, CF_3, CHF_2, CN, NO_2, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rC(O)OR^b$, $-(CH_2)_rOC(O)R^b$, $-(CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-(CH_2)_rNR^bC(O)OR^e$, $-NR^bC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)R^e$, $-S(O)_2R^e$, C_{1-6} alkyl substituted with 0-3 R^f, C_{1-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^a, C_{2-6} alkynyl substituted with 0-3 R^a, $-(CH_2)_r$-3-14 membered carbocycle or $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^f;

R^b is hydrogen, C_{1-6} alkyl substituted with 0-3 R^d, C_{1-6} haloalkyl, C_{3-6} cycloalkyl substituted with 0-2 R^d, or $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^f or $(CH_2)_r$-phenyl substituted with 0-3 R^d;

R^e is C_{1-6} alkyl substituted with 0-3 R^f, $(CH_2)_r$-C_{3-6} cycloalkyl substituted with 0-3 R^f or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^d at each occurrence is independently hydrogen, F, Cl, Br, OCF_3, CF_3, CN, NO_2, $-OR^e$, $-(CH_2)_rC(O)R^e$, $-NR^eR^e$, $-NR^eC(O)OR^e$, C_{1-6} alkyl or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^e at each occurrence is independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl and $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^f independently at each occurrence is hydrogen, halo, CN, NH_2, OH, C_{3-6} cycloalkyl, CF_3, $O(C_{1-6}$alkyl) or a $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$;


p is 0, 1, or 2; and

r is 0, 1, 2, 3, or 4.

15. The use of claim 14, wherein R^2 is $-C(O)R^{2a}$; or C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl or pyrrolopyridinyl, each group substituted by 0-4 groups selected from R^{2a}.

16. The use of claim 14 or 15, wherein both R^4 and R^5 are hydrogen.

~~17. The use of any one of claims 14 to 16, wherein the compound has the following formulae:~~



~~or~~

~~or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:~~

~~R^1 is H or C_{1-3}alkyl substituted by 0-7 R^{1a};~~

~~R^{1a} at each occurrence is independently hydrogen, deuterium or halogen;~~

~~R^2 is $-C(O)R^{2a}$; or C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, quinolinyl or pyrrolopyridinyl, each group substituted by 0-4 groups selected from R^{2a};~~

~~R^{2a} at each occurrence is independently hydrogen, =O, halo, CN, $-(CH_2)_rOR^b$, $-(CH_2)_rC(O)R^b$, $-NR^bC(O)R^e$, $-C(O)OR^b$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-S(O)_pNR^{11}R^{11}$, $-C_{1-6}$alkyl substituted with 0-3 R^a, C_{1-6} haloalkyl, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^a or a $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-2 R^a;~~

~~R^3 is C_{3-10} cycloalkyl, a C_{6-10} aryl, or a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, each group substituted with 0-4 R^{3a};~~

~~R^{3a} at each occurrence is independently hydrogen, halo, OCF_3, CF_3, CHF_2, CN, $-(CH_2)_rOR^b$, $-(CH_2)_rSR^b$, $-(CH_2)_rC(O)R^b$, $-(CH_2)_rNR^{11}R^{11}$, $-(CH_2)_rC(O)NR^{11}R^{11}$, $-(CH_2)_rNR^bC(O)R^e$, $-S(O)_pNR^{11}R^{11}$, $-NR^bS(O)_pR^e$, $-S(O)_pR^e$, C_{1-6} alkyl substituted with 0-3 R^a, C_{1-6} haloalkyl, a $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-3 R^a or a $-(CH_2)_r$-5-10 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^a;~~

~~or two R^{3a}, together with the atoms to which they are attached, combine to form a fused ring wherein that ring is selected from phenyl and a 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O, each fused ring substituted, as valence allows, by 0-3 R^a;~~

~~R^{11} at each occurrence is independently hydrogen, C_{1-4} alkyl substituted with 0-3 R^f or C_{3-6}cycloalkyl substituted with 0-1 R^f;~~

R^a at each occurrence is hydrogen, =O, F, $-(CH_2)_rOR^b$ or C_{1-6}alkyl substituted with 0-3 R^f;

R^b is hydrogen, C_{1-6} alkyl substituted with 0-3 R^d, C_{1-6} haloalkyl, C_{3-6} cycloalkyl substituted with 0-2 R^d, or $-(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$ substituted with 0-3 R^f; or $(CH_2)_r$ phenyl substituted with 0-3 R^d;

R^e is C_{1-6} alkyl substituted or C_{3-6} cycloalkyl, each group substituted with 0-3 R^f;

R^d at each occurrence is independently hydrogen, F, Cl, Br or -OH;

R^f at each occurrence is independently hydrogen, halo, CN, OH or $O(C_{1-6}$alkyl);


p is 0, 1 or 2; and


r is 0, 1 or 2.


18. The use of any one of claims 14 to 17, wherein R^2 is pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl or quinolinyl, each group substituted with 0-3 R^{2a}.

19. The use of any one of claims 14 to 17, wherein R^2 is $-C(O)R^{2a}$; or C_{1-6}alkyl, C_{3-6}cycloalkyl or phenyl substituted with 0-3 R^{2a}.

20. The use of any one of claims 14 to 18, wherein R^2 is:







~~21. The use of any one of claims 14 to 20, wherein R^3 is phenyl, cyclopentyl, cyclohexyl, triazolyl, oxadiazolyl, pyrimidinyl, tetrazolyl, pyrazolyl, thiazolyl, furanyl, or pyranyl, each group substituted with 0-4 R^{3a}. (Especially phenyl substituted with 0-4 R^{3a}).~~

~~22. The use of any one of claims 14 to 21, wherein:~~

~~R^{3a} at each occurrence independently is hydrogen, Ph, CN, NH_2, OCF_3, OR^b, halo, cycloalkyl, $C(O)NR^{11}R^{11}$, $S(O)_2NR_{11}R_{11}$, $C(O)R^b$, SO_pR^e, $NR^bSO_pR^e$, $NR^bC(O)R^e$, haloalkyl, CN, 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O substituted with 0-3 R^a and C_{1-6} alkyl substituted with 0-3 R^a; or~~

~~one R^{3a} and a second R^{3a}, together with the atoms to which they are attached, combine to form a fused 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O or phenyl;~~

~~R^{11} at each occurrence independently is hydrogen, C_{3-6} cycloalkyl substituted with 0-3 R^f, or C_{1-4}alkyl substituted with 0-1 R^f;~~

~~R^a independently at each occurrence is C_{1-6} alkyl substituted with 0-3 R^f, halo (F) or OR^b;~~

R^b independently at each occurrence is hydrogen, 5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, S or O substituted with 0-3 R^f, or C_{1-6} alkyl substituted with 0-3 R^d;


R^d independently at each occurrence is F, Cl, Br or OH;

R^e independently at each occurrence is C_{1-6} alkyl or C_{3-6} cycloalkyl, each group substituted with 0-3 R^f substituted with 0-3 R^f;

R^f independently at each occurrence is hydrogen, halo or OH; and

p is 2.

23. The use of any one of claims 14 to 22, wherein:

R^3 is 

;

R^{3aa} is $S(O)_pR^e$, OR^b, chloro, F, CN, NH_2, $C(O)NR^{11}R^{11}$, $NR^bSO_pR^e$, $NR^bC(O)R^e$, C_{1-6} alkyl substituted with 0-3 R^a or a 5- to 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S substituted with 0-3 R^{3a}; (especially, R^{3aa} is $S(O)_2$Me or OMe)

R^{3ab}, R^{3ac}, or R^{3ad} are independently hydrogen, Cl, F, Br, CN, OR^b, C_{1-6} alkyl substituted 0-3 R^a; $C(O)NR^{11}R^{11}$, $C(O)R^b$, S(O)pRc, or a 4-7 membered heterocycle containing1-3 heteroatoms selected from N, O, and S substituted with 0-3 R^a; (especially R^{3ab}, R^{3ac}, or R^{3ad} are independently, hydrogen or 5-6 membered heterocycle containing1-3 heteroatoms selected from N, O, and S substituted with 0-2 R^a;

R^{11} at each occurrence independently is hydrogen, cyclopropyl substituted with 0-3 R^f or C_{1-4}alkyl substituted with 0-3 R^f;

R^a at each occurrence independently is C_{1-6} alkyl substituted with 0-3 R^f, OR^b or halo;

R^b at each occurrence independently is hydrogen, C_{1-6} alkyl substituted with 0-2 R^d or a 5- to 7-membered heterocycle containing 1-3 heteroatoms selected from N, O and S;

R^e at each occurrence independently is C_{1-6} alkyl substituted with 0-3 R^f;

R^d at each occurrence independently is F or OH;


~~R^f at each occurrence independently is halo or OH; and~~









~~p is 0-2.~~








~~24. The use of claim 23, wherein R^{3aa} is $S(O)_pR^e$ or $C(O)NR^{11}R^{11}$.~~







~~25. The use of claim 23, wherein R^{3aa} is OR^b.~~



~~26. The use of any one of claims 14 to 24, wherein R^3 is:~~



5